RT Journal Article
SR Electronic
T1 DNA Methylation-Derived Immune Cell Proportions and Cancer Risk, Including Lung Cancer, in Black Participants
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.09.24307118
DO 10.1101/2024.05.09.24307118
A1 Semancik, Christopher S.
A1 Zhao, Naisi
A1 Koestler, Devin C.
A1 Boerwinkle, Eric
A1 Bressler, Jan
A1 Buchsbaum, Rachel J.
A1 Kelsey, Karl T.
A1 Platz, Elizabeth A.
A1 Michaud, Dominique S.
YR 2024
UL http://medrxiv.org/content/early/2024/05/09/2024.05.09.24307118.abstract
AB Prior cohort studies assessing cancer risk based on immune cell subtype profiles have predominantly focused on White populations. This limitation obscures vital insights into how cancer risk varies across race. Immune cell subtype proportions were estimated using deconvolution based on leukocyte DNA methylation markers from blood samples collected at baseline on participants without cancer in the Atherosclerosis Risk in Communities (ARIC) Study. Over a mean of 17.5 years of follow-up, 668 incident cancers were diagnosed in 2,467 Black participants. Cox proportional hazards regression was used to examine immune cell subtype proportions and overall cancer incidence and site-specific incidence (lung, breast, and prostate cancers). Higher T regulatory cell proportions were associated with statistically significantly higher lung cancer risk (hazard ratio = 1.22, 95% confidence interval = 1.06-1.41 per percent increase). Increased memory B cell proportions were associated with significantly higher risk of prostate cancer (1.17, 1.04-1.33) and all cancers (1.13, 1.05-1.22). Increased CD8+ naïve cell proportions were associated with significantly lower risk of all cancers in participants ≥55 years (0.91, 0.83-0.98). Other immune cell subtypes did not display statistically significant associations with cancer risk. These results in Black participants align closely with prior findings in largely White populations. Findings from this study could help identify those at high cancer risk and outline risk stratifying to target patients for cancer screening, prevention, and other interventions. Further studies should assess these relationships in other cancer types, better elucidate the interplay of B cells in cancer risk, and identify biomarkers for personalized risk stratification.Competing Interest StatementDr. Karl Kelsey is a founder and scientific advisor to Cellintec, which had no role in this research. Otherwise, the authors have no conflicts of interest to report. Funding StatementThis work was supported by the Jennifer M. Bjercke Scholar Award Fund for Breast Cancer Research at Tufts Medical Center (awarded to Dr. Dominique Michaud), which provided support for the analysis and writing of this manuscript. The Atherosclerosis Risk in Communities study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under Contract nos. (75N92022D00001, 75N92022D00002, 75N92022D0003, 75N92022D0004, 75N92022D0005). Funding was also supported by 5RC2HL102419 and R01NS087541. Studies on cancer in ARIC are also supported by the National Cancer Institute (U01 CA164975). The content of this work is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the US Government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Atherosclerosis Risk in Communities (ARIC) study protocol and recruitment of participants was approved by institutional review boards at each site and participants gave informed consent. The Johns Hopkins University IRB approved cancer-related studies using ARIC cohort data.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesDue to its proprietary nature, supporting data from the Atherosclerosis Risk in Communities cohort cannot be made openly available. Further information about the data and conditions for access are available at the Atherosclerosis Risk in Communities website at https://aric.cscc.unc.edu/aric9/.